ArticleNanoscale research letters2015
Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent.
Article in Nanoscale research letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.ACS applied bio materials · 2024Article
- Platinum nanoparticles labelled with iodine-125 for combined "chemo-Auger electron" therapy of hepatocellular carcinoma.Nanoscale advances · 2023Article
- The Role of Integrins for Mediating Nanodrugs to Improve Performance in Tumor Diagnosis and Treatment.Nanomaterials (Basel, Switzerland) · 2023Review
- Recent Progress of Gold-Based Nanostructures towards Future Emblem of Photo-Triggered Cancer Theranostics: A Special Focus on Combinatorial Phototherapies.Pharmaceutics · 2023Review
- Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload.Nanomaterials (Basel, Switzerland) · 2022Article
- Methods for Radiolabelling Nanoparticles: SPECT Use (Part 1).Biomolecules · 2022Review
- Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models.International journal of molecular sciences · 2022Article
- Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.Bioengineering & translational medicine · 2022Review
- A detailed experimental and Monte Carlo analysis of gold nanoparticle dose enhancement using 6 MV and 18 MV external beam energies in a macroscopic scale.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2021Article
- The Rational Design and Biological Mechanisms of Nanoradiosensitizers.Nanomaterials (Basel, Switzerland) · 2020Review
- Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.Journal of nanobiotechnology · 2019Review
- Evaluation of Brain Nuclear Medicine Imaging Tracers in a Murine Model of Sepsis-Associated Encephalopathy.Molecular imaging and biology · 2018Article
- Chiral ruthenium(ii) complex as potent radiosensitizer ofRSC advances · 2018Article
- Strategies on Nanodiagnostics and Nanotherapies of the Three Common Cancers.Nanomaterials (Basel, Switzerland) · 2018Review
- RGDfK-functionalized gold nanorods bind only to activated platelets.Journal of biomedical materials research. Part A · 2017Article
- Synthesis and Bioevaluation of Iodine-131 Directly Labeled Cyclic RGD-PEGylated Gold Nanorods for Tumor-Targeted Imaging.Contrast media & molecular imaging · 2017Article
- Chemisorption of iodine-125 to gold nanoparticles allows for real-time quantitation and potential use in nanomedicine.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2017Article
- Article
- Size effect of Au/PAMAM contrast agent on CT imaging of reticuloendothelial system and tumor tissue.Nanoscale research letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research interests on radiosensitive property of gold nanoparticles (GNPs) are rapidly raised because of the extensively proved in vitro effectiveness and clinical necessity. However, the issue of targeted accumulation of GNPs in tumor tissues hindered the transference to in vivo applications. In this study, hybrid nano-sized cyclic Arg-Gly-Asp-conjugated GNPs (cRGD-GNPs) integrated with radioactive iodine-125 was fabricated as tumor-targeted radiosensitizer. Therapeutic effects, including acute apoptosis (2 days post treatment) and long-term influence (up to 21 days), were investigated on NCI-H446 tumor-bearing mice via Tc-99 m-Annexin V SPECT and volume measurements, respectively. Apoptosis and volume loss were consistent in showing that tumor growth was effectively suppressed via the treatment of (125)I-cRGD-GNP sensitized radiotherapy (RT), a more significantly radiosensitive effect than the treatment of non-targeted GNPs with RT, RT treatment alone, and no treatment. SPECT/CT images showed that the uptake of cRGD-GNPs by tumor tissues reached the peak target/non-target value of 4.76 at around 2 h post injection, and dynamic radioactivity monitoring showed that (125)I-cRGD-GNPs maintained about 2.5% of injected dosage at 55 h post injection. For long-term influence, a significant radiosensitized RT-induced volume loss was observed. Hence, cyclic RGD conjugation makes the GNP-based radiosensitizer tumor targeting, offering a new modality for enhancing radiotherapeutic efficacy. Additionally, the introduction of I-125 serves as both a therapeutic factor and a radiotracer for in vivo tracking of GNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.